Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 Diabetes
Authors' conclusion
The use of Fiasp and Lyumjev during Boost or Ease-off resulted in comparable safety and efficacy to using insulin aspart and lispro.
Study context
- Population
- Individuals with T1D using the Cambridge hybrid closed-loop system; Fiasp vs aspart study and Lyumjev vs lispro study2 crossover studies · Fiasp vs aspart study 25 · Lyumjev vs lispro study 26
- Comparison
- Ultra-rapid insulins (Fiasp, Lyumjev) vs standard insulins (insulin aspart, insulin lispro) during Boost and Ease-off of the Cambridge hybrid closed-loop system
Methodological detailsdouble-blind, randomized
- Double-blind
- Randomized
Primary result
As reported in the abstract
Duration of Boost use
P = 0.01
Further findings
| Outcome | Fiasp | Insulin aspart | P value |
|---|---|---|---|
| Mean glucose on Boost initializationFiasp vs Insulin aspart | mean 238 ± 62 mg/dL | mean 218 ± 45 mg/dL | P = 0.08 |
| Glucose change 120 minutes after Boost initializationFiasp vs Insulin aspart · greater reduction with Fiasp | mean −59 ± 34 mg/dL | mean −43 ± 31 mg/dL | P = 0.02 |
Sensor glucose endpoints during Boost or Ease-off
- No statistically significant differences between Fiasp and aspart
- No statistically significant differences between Lyumjev and insulin lispro
Safety
- No safety issues using Boost and Ease-off with ultra-rapid insulins
Original publication
Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 Diabetes. J Diabetes Sci Technol. Published 18 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →